ALK and non-small cell lung carcinoma: These findings were robust across various scenario analyses.<h4>Conclusion</h4>Using alectinib in postoperative adjuvant therapy significantly reduces both the recurrence rate and recurrence-related treatment costs for stage IB (tumor ≥ 4 cm) to IIIA ALK+ NSCLC patients, compared to platinum-based chemotherapy.